DiNAQOR Bolsters Leadership Team with Key Appointments to Drive Next-Generation Biotech Ventures

DiNAQOR AG, an innovative health technology group advancing early-stage drug development, has announced strategic leadership appointments that reinforce its model as a life science company builder. The company focuses on creating, scaling, and partnering next-generation biotechnology ventures by enabling advanced, human-relevant nonclinical testing methods.

Dr. Christian Thirion has been appointed Chief Executive Officer and Delegate of the Board of Directors of DiNATEQ AG, the recently established DiNAQOR spin-out focused on the clinical translation of the closed-loop loco-regional perfusion (LRP) delivery platform. Concurrently, Dr. Thirion assumes the newly created role of Chief Strategy and Business Development Officer of DiNAQOR AG, where he will lead group-wide corporate strategy, strategic partnerships, and M&A activities.

Dr. Thirion brings over two decades of entrepreneurial and executive leadership experience in the life sciences industry. He founded Sirion Biotech and led it as its long-standing CEO, building the company into a global market leader in viral vector engineering and AAV-based gene delivery. Under his leadership, Sirion Biotech became a preferred partner to leading pharmaceutical and biotechnology companies worldwide and was ultimately acquired by PerkinElmer in a landmark transaction. Johannes Holzmeister, Founder of the DiNAQOR Group and Chairman and CEO of DiNAQOR AG, stated, "Christian is a rare combination of visionary entrepreneur, disciplined operator, and trusted partner to global pharmaceutical companies. His success in building Sirion Biotech from a pioneering start-up into a market-leading company speaks for itself."

Dr. Thirion added, "DiNAQOR has built an exceptional ecosystem for turning scientific innovation into impactful biotechnology companies. The closed-loop perfusion platform represents a truly differentiated delivery technology with the potential to unlock multiple therapeutic modalities across organs. I am excited to lead DiNATEQ at this pivotal stage and, at the group level, to help shape DiNAQOR's long-term strategy, forge strong pharmaceutical partnerships, and continue building companies that address significant unmet medical needs."

In parallel, DiNAQOR Group AG announced the appointment of Dr. Josef El Andari as Chief Scientific Officer of DiNAQOR AG. Dr. El Andari has been with DiNAQOR for more than four years and has played a central role in advancing the company's scientific platforms, including the development of the closed-loop perfusion technology from early concept through publication in leading peer-reviewed journals. His expertise spans genomic medicine, translational research, and advanced viral vector technologies, with a particular focus on AAV design and bioengineering.

Dr. El Andari commented, "Over the past four years, DiNAQOR has evolved into a uniquely integrated innovation engine for advanced therapies. I am honored to take on the role of Chief Scientific Officer and to continue working with our teams and partners to translate rigorous science into therapies with real clinical impact. Our ambition is not only to innovate, but to do so in a way that is scalable, clinically relevant, and aligned with the highest scientific standards."

These appointments are significant as they strengthen DiNAQOR's operational and scientific leadership at a critical juncture. The company operates as a life science company builder, creating and scaling focused biotechnology companies around differentiated technology platforms. In addition to DiNATEQ AG, DiNAQOR has demonstrated its company-building and value-creation capabilities through successful strategic transactions, including the recent M&A of DiNAMIQS, a specialized adeno-associated virus (AAV) manufacturing and development company. For more information, visit https://www.dinaqor.com. The original release can be viewed on https://www.newmediawire.com.

The implications of these leadership changes are substantial for the biotechnology and pharmaceutical industries. By bringing in Dr. Thirion, who has a proven track record of building and exiting a successful biotech company, DiNAQOR signals its intent to accelerate the commercialization of its perfusion delivery platform and pursue strategic partnerships. Dr. El Andari's promotion ensures continuity in scientific innovation, which is crucial for advancing therapies for organ-specific diseases. For patients, this could mean faster translation of promising technologies into clinical trials and, ultimately, new treatments. For investors and partners, it underscores DiNAQOR's commitment to disciplined growth and value creation through its unique company-building model.